



Study of the Energy of Consciousness Healing Treatment on Physical, Structural, Thermal, and Behavioral Properties of Zinc Chloride

Mahendra Kumar Trivedi¹, Alice Branton¹, Dahryn Trivedi¹, Gopal Nayak¹, Alan Joseph Balmer¹, Dimitrius Anagnos¹, Janice Patricia Kinney¹, Joni Marie Holling¹, Joy Angevin Balmer¹, Lauree Ann Duprey-Reed¹, Vaibhav Rajan Parulkar¹, Parthasarathi Panda², Kalyan Kumar Sethi², Snehasis Jana^{2,*}

¹Trivedi Global, Inc., Nevada, USA

²Trivedi Science Research Laboratory Pvt. Ltd., Bhopal, India

Email address:

publication@trivedieffect.com (S. Jana)

*Corresponding author

To cite this article:

Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Alan Joseph Balmer, Dimitrius Anagnos, Janice Patricia Kinney, Joni Marie Holling, Joy Angevin Balmer, Lauree Ann Duprey-Reed, Vaibhav Rajan Parulkar, Parthasarathi Panda, Kalyan Kumar Sethi, Snehasis Jana. Study of the Energy of Consciousness Healing Treatment on Physical, Structural, Thermal, and Behavioral Properties of Zinc Chloride. *Modern Chemistry*. Vol. 5, No. 2, 2017, pp. 19-28. doi: 10.11648/j.mc.20170502.11

Received: February 24, 2017; **Accepted:** March 9, 2017; **Published:** April 1, 2017

Abstract: Zinc chloride is an important pharmaceutical/nutraceutical mineral for the prevention and treatment of several diseases. The objective of the current study was to investigate the impact of The Trivedi Effect[®]-Energy of Consciousness Healing Treatment (Biofield Energy Treatment) on physical, structural, thermal, and behavioral properties of zinc chloride using PXRD, PSD, FT-IR, UV-vis, and DSC analysis. Zinc chloride was divided into two parts – one part was control, while another part was treated with The Trivedi Effect[®] remotely by seven renowned Biofield Energy Healers and defined as The Trivedi Effect[®] treated sample. A significant alteration of the crystallite size and relative intensities of the PXRD peaks were observed in The Trivedi Effect[®] treated sample with respect to the control sample. A sharp peak at 2θ equal to 51.45° , which was observed in the control sample was disappeared in the treated sample. The average crystallite size of the treated sample was decreased by 2.13% compared with the control sample. The size of the particles at d_{10} , d_{50} , and d_{90} was decreased by 3.36%, 7.97%, and 11.51%, respectively in the treated sample compared with the control sample. The surface area of the treated sample was significantly increased by 5.69% compared with the control sample. The FT-IR spectroscopic analysis revealed that Zn-Cl stretching in the control was 646 cm^{-1} , whereas it was significantly shifted downward to 505 cm^{-1} in the treated sample. The UV-vis analysis exhibited that wavelength of the maximum absorbance (λ_{max}) of both the control and treated samples was at 196.4 nm. The DSC analysis exhibited that the melting and decomposition temperature were increased by 0.93% and 0.56%, respectively in the treated zinc chloride compared to the control sample. The enthalpy of fusion of the treated sample (338.27 J/g) was increased significantly by 33.84% compared with the control sample (252.75 J/g). The enthalpy of decomposition of the treated sample was increased by 3.78% compared with the control sample. The current study anticipated that The Trivedi Effect[®]-Energy of Consciousness Healing Treatment might lead to produce a new polymorphic form of zinc chloride, which would be more soluble, bioavailable, and thermally stable compared with the untreated compound. The treated sample could be more stable during manufacturing, delivery or storage conditions than the untreated sample. Hence, the treated zinc chloride would be very useful to design better nutraceutical/pharmaceutical formulations that might offer better therapeutic response against inflammatory diseases, immunological disorders, aging, stress, cancer, etc.

Keywords: Biofield Energy Healing Treatment, Consciousness Energy Healing Treatment, Biofield Energy Healers, The Trivedi Effect[®], Zinc Chloride, PXRD, Particle Size, DSC

1. Introduction

Zinc is an essential element in human and animal nutrition for its broad spectrum of biological activities. It plays an important role in catalytic, structural or regulation in enzymes in our body, which involved in the nucleic acid and protein metabolism as well as for the production of energy. Zinc also maintains the structural integrity of the biological membranes resulting in their protection against oxidative injury [1-2]. As a metallotherapeutic agent, zinc possesses various pharmacological activities include fertility enhancing, retino-protective, and putative antiviral activities [3]. Zinc is also used in the treatment of Wilson's disease [4]. It has also immunomodulatory and antioxidant activities [1]. Zinc is also used to prevent the development of several deficiency symptoms include parakeratosis, hypogeusia, anorexia, dysosmia, geophagia, hypogonadism, growth retardation, etc. [5-7]. Recently, it has been reported that zinc had increased the leukocyte count and phagocytic index, which potentiate the immunomodulatory effect along with *Glycyrrhiza glabra* [8]. Zinc chloride ($ZnCl_2$) is hygroscopic inorganic salt and highly soluble in water [9]. It is sometimes used in pharmaceutical industry as drug and diagnostic agent due to its powerful astringent and mild antiseptic properties [10]. It is also used in mouth-wash and deodorant preparations. Zinc chloride is used in as dentin desensitizer *i.e.* reduces the sensitivity of the teeth to heat and cold. The other applications of zinc chloride include protein precipitation and insulin preparation [10, 11]. Literature reported that zinc chloride has been used in the treatment of cancer as a destructive agent [12] and in the pluripotency maintenance of mouse embryonic stem cell through the regulation of STAT3 signaling pathway [13]. It can be used for the palliative treatment of canine and malignant skin wounds [14]. It has the opposite effect on locomotor behavior of rats [15]. Therefore, zinc chloride was considered as one of the component in the novel proprietary herbomineral formulation for the source of zinc ion. This herbomineral formulation is designed as nutraceutical supplement, and can be used for the prevention and treatment of various human disorders.

An élan vital or vital force which contributes the 'life' is preserved by every living organisms and known as prana by the Hindus, *qi* or *chi* by the Chinese, and *ki* by the Japanese. This is believed to co-relate with the soul, spirit and mind. This hypothetical vital force is considered as the Biofield Energy. The Biofield Energy is infinite, paradigmical and dynamic electromagnetic field surrounding the human body. It can freely flow between the human and environment that leads to the continuous movement or matter of energy [16, 17]. Thus, a human has the ability to harness energy from the earth, the "universal energy field" and transmit it to any living or nonliving object(s) around the globe. The objects always receive the energy and respond in a useful way. This process is known as Biofield Energy Healing Treatment [18, 19]. Biofield (Putative Energy Fields) based Energy Therapies are used worldwide to promote health and healing. The National Center of Complementary and Integrative Health (NCCIH) has been recognized and accepted Biofield Energy Healing as a

Complementary and Alternative Medicine (CAM) health care approach in addition to other therapies, medicines and practices such as natural products, deep breathing, yoga, Tai Chi, Qi Gong, chiropractic/osteopathic manipulation, meditation, massage, special diets, homeopathy, progressive relaxation, guided imagery, acupressure, acupuncture, relaxation techniques, hypnotherapy, healing touch, movement therapy, pilates, rolfing structural integration, mindfulness, Ayurvedic medicine, traditional Chinese herbs and medicines, naturopathy, essential oils, aromatherapy, Reiki, cranial sacral therapy and applied prayer (as is common in all religions, like Christianity, Hinduism, Buddhism and Judaism) [20]. Biofield Energy Treatment (The Trivedi Effect[®]) has been reported in numerous peer-reviewed science journals with significant outcomes in many scientific fields such as cancer research [21]; altered antimicrobial sensitivity of pathogenic microbes in microbiology [22-24], biotechnology [25, 26], genetics [27, 28]; changing the structure of the atom in relation to various metals, ceramics, polymers and chemicals in materials science [29, 30], altered physical and chemical properties of pharmaceuticals [31, 32], nutraceuticals [33, 34], organic compounds [35-37], and improved overall growth and yield of plants in agricultural science [38, 39]. The physicochemical properties such as particle size, crystalline structure, crystallite size, surface area, and thermal properties of a drug have a vital role in bioavailability as well as stability of the drug during processing, formulation, storage, and packaging [40, 41]. The particle size, specific surface area, crystalline nature, chemical and thermal behavior of an atom/ion might be altered by the Biofield Energy Healing Treatment (The Trivedi Effect[®]) through possible mediation of neutrinos [42]. By considering all these aspects, powder X-ray diffraction (PXRD), particle size distribution analysis (PSD), Fourier transform infrared (FT-IR) spectrometry, ultraviolet-visible (UV-vis) spectroscopy, and differential scanning calorimetry (DSC) analytical techniques were conducted in this study for the characterization of physical, structural, and thermal properties of the Biofield Energy Treated and untreated zinc chloride.

2. Materials and Methods

2.1. Chemicals and Reagents

Zinc chloride was procured from Tokyo Chemical Industry Co., Ltd. (TCI), Japan. All other chemicals used in the experiment were of analytical grade available in India.

2.2. The Trivedi Effect[®] - Energy of Consciousness Healing Treatment Strategies

Zinc chloride was one of the components of the new proprietary herbomineral formulation, developed by our research team and it was used *per se* as the test compound for the current study. The test compound was divided into two parts, one part of the test compound did not receive any sort of treatment and was defined as the untreated or control zinc chloride sample. The second part of the test compound was

treated with The Trivedi Effect® - Energy of Consciousness Healing Treatment (Biofield Energy Treatment) by a group of seven renowned Biofield Energy Healers remotely and was denoted as Biofield Energy Treated or The Trivedi Effect® sample. Six Biofield Energy Healers were remotely located in the U.S.A. and one of which was remotely located in Canada, while the test compound was located in the research laboratory of GVK Biosciences Pvt. Ltd., Hyderabad, India. This Biofield Energy Treatment was provided for 5 minutes through Healer's Unique Energy Transmission process remotely to the test compound under the laboratory conditions. None of the Biofield Energy Healers in this study visited the laboratory in person, nor had any contact with the compounds. Similarly, the control compound was subjected to "sham" healers for 5 minutes, under the same laboratory conditions. The sham healer did not have any knowledge about the Biofield Energy Treatment. After that, the Biofield Energy Treated and untreated samples were kept in similar sealed conditions and characterized thoroughly by PXRD, PSD, FT-IR, UV-visible spectroscopy, and DSC analysis.

2.3. Characterization

2.3.1. Powder X-Ray Diffraction (PXRD) Analysis

The PXRD analysis was accomplished on PANalytical X'pert Pro powder X-ray diffractometer system. The X-ray of wavelength 1.54056 Å was used. The data was collected in the form of a chart of the Bragg angle (2θ) vs. intensity, and a detailed table containing information on peak intensity counts, d value (Å), relative intensity (%), full width half maximum (FWHM) (θ°). From the PXRD results, the crystallite size (G) was calculated using X'pert data collector and X'pert high score plus processing software. The crystallite size (G) was calculated from the Scherrer equation [43, 44]. The method was based on the width of the diffraction patterns obtained in the X-ray reflected the crystalline region. The crystallite size (G) was calculated by using the following formula (1):

$$G = k\lambda / (b \cos \theta) \quad (1)$$

Where, k is the equipment constant (0.5), λ is the X-ray wavelength (0.154 nm); b in radians is the full-width at half of the peaks and θ the corresponding Bragg angle.

Percent change in crystallite size (G) was calculated using following equation (2):

$$\% \text{ change in crystallite size} = \frac{[G_{\text{Treated}} - G_{\text{Control}}]}{G_{\text{Control}}} \times 100 \quad (2)$$

Where, G_{Control} and G_{Treated} are the crystallite size of the control and Biofield Energy Treated samples, respectively.

A total of ~500.21 mg of the control and treated samples individually were used for the analysis and prepared by back loading technique using the sample preparation kit. The sample was spread on the holder ring in sufficient quantity to fill the ring cavity. It was then pressed down using powder press block and scrap the powder that was in surplus using a glass slide to get densely packed specimen. Consequently, the

bottom plate was placed onto the holder ring and clamp in position. The sample holder was then removed from the sample preparation table by turning it upside down. A smooth surface of sample was obtained to ensure optimum results.

2.3.2. Particle Size Distribution (PSD) Analysis

The average particle size and particle size distribution were analyzed using Malvern Mastersizer 2000, UK with a detection range between 0.01 μm to 3000 μm. The sample unit was filled with the dispersant medium and operated the stirrer at 2500 rpm. Alignment of the optics was done and the background measurement was taken. After the background measurement, the sample was added into the sample unit with constant monitoring the obscuration and stopped the addition of sample when the obscuration reached in between 15% to 20%. When the obscuration was stable, the measurement was taken twice and the average of two measurements was taken. The average histogram of the two measurements was recorded. The print out of the average histogram of the two measurements was documented. Along with histogram, the data was presented in table format which include particle size (μm). Also, the values at below 10% level (d₁₀), 50% level (d₅₀), and 90% level (d₉₀) were calculated from the histogram and the calculations such as surface area (m²/g) were done by using software Mastersizer 2000.

Percent change in particle size (d) for at below 10% level (d₁₀), 50% level (d₅₀), and 90% level (d₉₀) was calculated using following equation (3):

$$\% \text{ change in particle size} = \frac{[d_{\text{Treated}} - d_{\text{Control}}]}{d_{\text{Control}}} \times 100 \quad (3)$$

Where, d_{Control} and d_{Treated} are the particle size (μm) for at below 10% level (d₁₀), 50% level (d₅₀), and 90% level (d₉₀) of the control and treated samples, respectively.

Percent change in surface area (S) was calculated using following equation (4):

$$\% \text{ change in surface area} = \frac{[S_{\text{Treated}} - S_{\text{Control}}]}{S_{\text{Control}}} \times 100 \quad (4)$$

Where, S_{Control} and S_{Treated} are the surface area of the control and treated samples, respectively.

2.3.3. Fourier Transform Infrared (FT-IR) Spectroscopy

FT-IR spectroscopy of zinc chloride was performed on Spectrum two (Perkin Elmer, USA) Fourier transform infrared spectrometer with the frequency array of 400-4000 cm⁻¹ by using pressed KBr disk technique.

2.3.4. Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis

The UV-Vis spectral analysis was carried out using Shimadzu UV-2450 with UV Probe, Japan. The spectrum was recorded using 1 cm quartz cell that has a slit width of 1.0 nm. The wavelength range chosen for recording the spectra was 190-800 nm. The absorbance spectra (in the range of 0.2 to 0.9) and wavelength of maximum absorbance (λ_{max}) were recorded.

2.3.5. Differential Scanning Calorimetry (DSC)

Analysis was performed using the DSC Q20 (TA Instruments, USA) differential scanning calorimeter. A total of ~7.50 mg sample was weighed and sealed in aluminum

pans and equilibrated at 25°C and heated up to 450°C at the heating rate of 10°C/min under nitrogen gas as purge atmosphere with flow rate of 50 mL/min. The value for onset, endset, peak temperature, peak height (mJ or mW), peak area, and change in heat (J/g) for each peak were recorded.

Percent change in the decomposition temperature (T) was calculated using following equation (5):

$$\% \text{ change in melting point} = \frac{[T_{\text{Treated}} - T_{\text{Control}}]}{T_{\text{Control}}} \times 100 \quad (5)$$

Where, T_{Control} and T_{Treated} are the decomposition temperature of the control and treated samples, respectively.

Percent change in the enthalpy of decomposition (ΔH) was calculated using following equation (6):

$$\% \text{ change in enthalpy of decomposition} = \frac{[\Delta H_{\text{Treated}} - \Delta H_{\text{Control}}]}{\Delta H_{\text{Control}}} \times 100 \quad (6)$$

Where, $\Delta H_{\text{Control}}$ and $\Delta H_{\text{Treated}}$ are the enthalpy of decomposition of the control and treated samples, respectively.

3. Results and Discussion

3.1. Powder X-Ray Diffraction (PXRD) Analysis

The PXRD diffractograms of both the control and treated zinc chloride are shown in the Figure 1. The diffractograms displayed very sharp and intense peaks in their respective diffractogram indicating the crystalline nature of zinc chloride. PXRD data such as Bragg angle (2θ), relative intensity (%), full width half maximum (FWHM) (θ°), and crystallite size (G) for the control and Biofield Energy Treated zinc chloride are presented in the Table 1. The crystallite size was calculated with the help of Scherrer equation [43, 44]. The crystallite size of the control and Biofield Energy Treated samples were found

similar at 2θ equal to nearly 15.7°, 16.7°, 35.0°, 52.4°, and 57.5° (Table 1, entry 1, 2, 5, 10, and 12). Consequently, the crystallite size of the Biofield Energy Treated zinc chloride at 2θ equal to nearly 25.5°, 29.4°, 38.4°, 49.3°, 73.0°, 79.0°, 90.9°, and 92.0° (Table 1, entry 3, 4, 6, 8, and 17-20) was significantly increased in the range of 20% to 50% compared with the control sample. On the other hand, the crystallite size of the treated zinc chloride at 2θ equal to nearly 48.8°, 56.3°, 58.4°, 61.9°, 63.3°, and 70.7° (Table 1, entry 7, 11, and 13-16) was significantly decreased in the range of 20% to 50% with respect to the control sample. However, the average crystallite size of the Biofield Energy Treated sample was reduced by 2.13% (Table 1, entry 21) with respect to the control sample.




Figure 1. PXRD diffractogram of the control and Biofield Energy Treated zinc chloride.

Table 1. PXRD data of the control and Biofield Energy Treated zinc chloride.

Entry No.	Bragg angle (2θ)		Relative Intensity (%)		FWHM ($^{\circ}2\theta$)		Crystallite size (G, nm)		
	Control	Treated	Control	Treated	Control	Treated	Control	Treated	% change*
1	15.72	15.65	22.72	59.13	0.1004	0.1004	44.26	44.25	-0.01
2	16.73	16.64	20.47	19.67	0.0669	0.0669	66.50	66.49	-0.01
3	25.55	25.48	72.86	81.57	0.1338	0.1004	33.73	44.95	33.25
4	29.43	29.36	33.98	74.58	0.0669	0.0502	68.03	90.65	33.25
5	35.03	34.98	85.14	50.04	0.0502	0.0502	91.96	91.95	-0.01
6	38.39	38.32	77.55	39.85	0.0612	0.0502	76.17	92.85	21.89
7	48.77	48.74	100.00	90.64	0.0612	0.1224	79.00	39.50	-50.01
8	49.29	49.28	61.18	100.00	0.1020	0.0816	47.50	59.37	24.99
9	51.45	Absent	16.46	NA	0.0816	NA	59.91	0.00	0.00
10	52.40	52.32	20.50	20.21	0.0816	0.0816	60.15	60.13	-0.03
11	56.33	56.25	31.27	27.35	0.0612	0.0816	81.63	61.20	-25.03
12	57.51	57.46	11.60	21.17	0.0816	0.0816	61.57	61.56	-0.02
13	58.38	58.39	26.87	26.04	0.0816	0.1020	61.83	49.47	-20.00
14	61.86	61.82	9.17	34.06	0.0816	0.1020	62.93	50.34	-20.02
15	63.28	63.22	9.14	32.93	0.0612	0.0816	84.55	63.39	-25.02
16	70.67	72.20	28.61	41.77	0.0612	0.1020	88.26	53.47	-39.42
17	72.28	73.89	19.55	19.14	0.1020	0.0816	53.50	67.58	26.32
18	79.07	79.00	8.97	12.71	0.1020	0.0816	56.03	70.01	24.94
19	90.86	90.84	8.68	11.94	0.1224	0.0816	51.35	77.01	49.97
20	92.03	91.98	14.83	17.75	0.1224	0.1020	51.89	62.24	19.95
21	Average crystallite size*						64.94	63.56	-2.13

FWHM: Full width half maximum, *denotes the percentage change in the crystallite size of the Biofield Energy Treated sample with respect to the control sample.

The PXRD diffractogram of the Biofield Energy Treated zinc chloride showed greater intensity at Bragg's angle (2θ) equal to 49.28° (Table 1, entry 8), whereas it was observed at 48.77° (Table 1, entry 7) in the control sample. A sharp peak at 2θ equal to 51.45° (Figure 1) was observed in the control sample, whereas this peak was absent in the treated sample. In addition, the XRD peaks at 2θ equal to 70.67° and 72.28° (Table 1, entry 16 and 17) in the control sample were shifted to 72.20° and 73.89° (Table 1, entry 16 and 17) in the treated sample. These results indicated the relative intensities of the XRD peaks (Table 1) in the treated sample were significantly altered as compared to the control sample. It has been found in the scientific literature that XRD relative intensity of each diffraction face on the crystalline compound changes according to the crystal morphology [45]. Thus, it is presumed that the energy transferred through the Biofield Energy Healing Treatment probably altered the shape and size of molecules, which might be responsible for an alteration in the relative intensities and crystallite size in the treated sample as compared to the control sample.

Raza *et al.* reported that changes in XRD pattern provide the proof of polymorphic transitions [46, 47]. Crystal habit, size, and even polymorphic form of a drug have a significant effect on the drug solubility, dissolution, and bioavailability. It has been reported in the literature that alteration in the crystal morphology had the significant impact on *in vitro* dissolution rate, with prospective for improving bioavailability [41]. Hence, PXRD study revealed that Biofield Energy Healing Treatment might introduced a new polymorphic form of zinc chloride, which could have improved bioavailability compared with the control sample.

3.2. Particle Size Analysis

The particle size data (d_{10} , d_{50} , and d_{90}) of both the control and treated zinc chloride were investigated and the results are presented in the Table 2.

Table 2. Particle size data (d_{10} , d_{50} , and d_{90}) and surface area of the control and Biofield Energy Treated zinc chloride.

Parameter	d_{10} (μm)	d_{50} (μm)	d_{90} (μm)	Surface area (m^2/g)
Control	0.98	2.76	6.69	2.99
Treated	0.95	2.54	5.92	3.16
Percent change (%)*	-3.06	-7.97	-11.51	5.69

*denotes the percentage change in the particle size data (d_{10} , d_{50} , and d_{90}) and surface area of the Biofield Energy Treated sample with respect to the control sample.

It was evident that Biofield Energy Treatment (The Trivedi Effect[®] treated) has the ability to reduce the particle size (d_{10} , d_{50} , and d_{90}) of zinc chloride with respect to the control sample. The size of the particles at below 10% level (d_{10}), 50% level (d_{50}), and 90% level (d_{90}) was decreased by 3.06%, 7.97%, and 11.51%, respectively in the Biofield Energy Treated sample compared to the control sample.

Particle size as well as the surface area have a major effect on dissolution of a compound in a solvent, because the surface energy influenced by surface area and chemical affinity is the driving factor for dissolution efficiency [48, 49]. The surface area for both the control and Biofield Energy Treated zinc chloride samples was analyzed and the results are presented in Table 2. The control sample showed

surface area of 2.99 m²/g and it was increased to 3.16 m²/g in the Biofield Energy Treated zinc chloride. The result showed 5.69% increase in surface area of the Biofield Energy Treated sample with respect to the control sample.

Poorly crystallized compounds possess more surface area and higher exchange capacities than well-crystallized compounds [50]. In addition, the variation of the crystal morphology in the Biofield Energy Treated sample, which was well-supported from PXRD data, may cause to alter the surface area of the Biofield Energy Treated zinc chloride compared with the control sample. It has been well established that the particle size, shape and surface area of pharmaceutical compounds have an important impact on solubility, dissolution and *in vivo* bioavailability, as well as supports the designing of new drug delivery systems [51, 52]. Reducing particle size and higher surface area would enhance the solubility of the solid particles, and consequently would increase the dissolution rate and bioavailability [53]. Thus, it is assumed that the Biofield Energy Treated zinc chloride might be dissolved and absorbed at a faster rate and may possibly have more bioavailability than untreated zinc chloride.

3.3. Fourier Transform Infrared (FT-IR) Spectroscopy

The FT-IR spectra of the control and Biofield Energy Treated samples of zinc chloride are presented in the Figure 2. The characteristic peak were observed at 3496, 1616, 1403, and 646 cm⁻¹ in the control FT-IR spectrum (Figure 2). On the other hand, The FT-IR spectrum of the Biofield Energy Treated zinc chloride (Figure 2) showed the notable absorption bands at 3590 cm⁻¹, 3519 cm⁻¹, 1931 cm⁻¹, 1608 cm⁻¹, 993 cm⁻¹, and 505 cm⁻¹. The strong and broad absorption band centered at 3496 cm⁻¹ and the H-O-H bending motion at 1616 cm⁻¹ that were due to the presence of the lattice water were found in the control FT-IR spectrum (Figure 2). Consequently, the peaks for the lattice water were observed in the spectrum of the Biofield Energy Treated zinc chloride (Figure 2) at 3590, 3519, and 1608 cm⁻¹. From the literature, it has been found that metal stretching absorption band for inorganic materials was found in the 750-100 cm⁻¹ region [54]. In control spectrum, metal-halogen (Zn-Cl) stretching was shown at 646 cm⁻¹, whereas it was shifted downward in the Biofield Energy Treated sample at 505 cm⁻¹. Overall, FT-IR results suggest that there may be a significant impact of Biofield Energy Treatment on zinc chloride at the atomic level to reduce the force constant of Zn-Cl bonds.




Figure 2. FT-IR spectra of the control and Biofield Energy Treated zinc chloride.

3.4. Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis

The UV-visible spectra of both the control and treated zinc chloride are presented in the Figure 3. The wavelength of the most intense UV-Vis absorbance (λ_{max}) of the both the control and Biofield Energy Treated samples were observed in their UV-Vis spectra (Figure 3) at 196.0 nm with a minor shift of absorbance maxima from 2.0317 (control) to 1.9653 in the treated sample. The UV absorbance occurs due to the diverse type of energy transitions from the singlet to the singlet excited state such as $\sigma \rightarrow \sigma^*$, $n \rightarrow \pi^*$, and $\pi \rightarrow \pi^*$. These type of electronic transitions are occurred when the difference in energy between the lowest unoccupied molecular orbital (LUMO) and the highest occupied molecular orbital (HOMO) is significantly higher than the activation energy of the compound [55]. The UV-vis spectroscopic analysis of zinc chloride displayed no change in the λ_{max} of the treated sample as compared to the control sample. Thus, the structural configuration or activation energy of the treated sample was not changed as compared to the control sample.

3.5. Differential Scanning Calorimetry (DSC) Analysis

The DSC thermograms of the control and treated zinc chloride are presented in the Figure 4. The melting/decomposition temperature and enthalpy of fusion/decomposition of the control and treated zinc chloride

are presented in the Table 3. The melting/fusion temperature was increased by 0.93% in the treated zinc chloride (315.12°C) as compared to the control sample (312.23°C). The onset and endset melting temperatures of the treated sample were also increased by 2.50% and 0.62%, respectively compared with the control sample. The enthalpy of fusion (ΔH_{fusion}) of the control and treated zinc chloride were 252.75 J/g and 338.27 J/g, respectively. The ΔH_{fusion} of the treated sample was increased significantly by 33.84% compared with the control sample. Similarly, the decomposition temperature of the treated zinc chloride (385.06°C) was increased by 0.56% compared to the control sample (382.90°C). The onset and endset decomposition temperatures of the treated sample were also increased by 0.19% and 0.50%, respectively compared with the control sample. The enthalpy of decomposition ($\Delta H_{\text{decomposition}}$) of the control and treated zinc chloride were 1173.25 J/g and 1217.56 J/g, respectively. The $\Delta H_{\text{decomposition}}$ of the treated sample was increased by 3.78% compared with the control sample. It is anticipated that Biofield Energy Treatment might enhance the internal energy in zinc chloride that leads to increase in the melting/decomposition temperature and the enthalpy of fusion/decomposition as well as thermal stability of the Biofield Energy Treated sample. The enhanced thermal stability of a drug is an advantage in the maintenance of the product in long term storage condition throughout the shelf-life for any pharmaceutical formulations [56].

Table 3. The enthalpy of decomposition (J/g) and decomposition temperature (°C) values of the control and Biofield Energy Treated zinc chloride.

Endothermic peak	Description	T _{onset} (°C)	T _{peak} (°C)	T _{endset} (°C)	ΔH (J/g)
	Control sample	297.34	312.23	317.13	252.75
Endothermic peak	Biofield Energy Treated sample	304.78	315.12	319.09	338.27
% Change*		2.50	0.93	0.62	33.84
	Control sample	378.91	382.90	385.25	1173.25
Exothermic peak	Biofield Energy Treated sample	379.63	385.06	387.19	1217.56
% Change*		0.19	0.56	0.50	3.78

T_{onset}: Onset decomposition temperature, T_{peak}: Peak decomposition temperature, T_{endset}: Endset decomposition temperature, ΔH: Enthalpy of fusion/decomposition, *denotes the percentage change of the Biofield Energy Treated sample with respect to the control sample.




Figure 3. UV-Vis spectra of the control and Biofield Energy Treated zinc chloride.




Figure 4. DSC thermograms of the control and Biofield Energy Treated zinc chloride.

4. Conclusions

The current study revealed that the Biofield Energy Healing Treatment (The Trivedi Effect[®]) had the notable effects on the physicochemical and thermal properties of zinc chloride. The PXRD data displayed the significant alteration of the crystallite size and relative intensities of the XRD peaks in The Trivedi Effect[®] sample compared with the control sample. A sharp peak at 2θ equal to 51.45° , which was found in the control sample was disappeared in the treated sample. The average crystallite size of the treated sample was decreased by 2.13% compared with the control sample. The size of the particles at d_{10} , d_{50} , and d_{90} values was decreased by 3.36%, 7.97%, and 11.51%, respectively in the treated sample compared with the control sample. The surface area of the treated sample was significantly increased by 5.69% compared with the control sample. The FT-IR spectroscopic analysis revealed that Zn-Cl stretching vibration in the control sample was 646 cm^{-1} , whereas it was significantly shifted downward to 505 cm^{-1} in the treated sample. The DSC analysis exhibited that the melting and decomposition temperature were increased by 0.93% and 0.56%, respectively in the treated zinc chloride compared to the control sample. The enthalpy of fusion of the treated sample (338.27 J/g) was increased significantly by 33.84% compared with the control sample (252.75 J/g). The enthalpy of decomposition of the treated sample was increased by 3.78% compared with the control sample. The melting and decomposition temperature the treated zinc chloride were increased compared with the control sample. The DSC analysis exhibited that the treated zinc chloride was found to be thermally more stable compared with the control sample. Briefly, The Trivedi Effect[®] - Energy of Consciousness Healing Treatment might introduce a new thermally stable polymorphic form of zinc chloride that could be more soluble, bioavailable, and thermally stable compared with

the untreated compound. The treated sample could be more stable during manufacturing, delivery or storage conditions than the untreated sample. Hence, the Biofield Energy Treated zinc chloride would be very useful to design better nutraceutical and/or pharmaceutical formulations that might offer better therapeutic response against inflammatory diseases, immunological disorders, aging, stress, cancer, Wilson's disease, viral diseases, parakeratosis, hypogeusia, anorexia, dysosmia, geophagia, hypogonadism, growth retardation, etc.

Abbreviations

DSC: Differential scanning calorimetry, FT-IR: Fourier transform infrared spectroscopy, FWHM: Full width half maximum, G: Crystallite size, HOMO: Highest energy occupied molecular orbital, LUMO: Lowest energy unoccupied molecular orbital, T_{onset} : Onset decomposition temperature, T_{peak} : Peak decomposition temperature, T_{endset} : Endset decomposition temperature, ΔH : enthalpy of fusion/decomposition, UV-vis: Ultraviolet-visible spectroscopy, PSD: Particle size distribution; PXRD: Powder X-ray diffraction.

Acknowledgements

The authors gratefully acknowledged to GVK Biosciences Pvt. Ltd., Trivedi Science, Trivedi Global, Inc. and Trivedi Master Wellness for their assistance and support during the work.

References

- [1] Ronconi L, Sadler PJ. (2008) Applications of heteronuclear NMR spectroscopy in biological and medicinal inorganic chemistry. *Coordn Chem Rev* 252: 2239-2277.

- [2] Berg JM, Shi Y. (1996) The galvanization of biology: A growing appreciation for the roles of zinc. *Science* 271: 1081-1085.
- [3] Higdon JV, Ho E. (2005) In: M. Gielen, E. R. T. Tiekink (Eds.), *Metallotherapeutic drugs and metal-based diagnostic agents: The use of metals in medicine*, Wiley-VCH, Weinheim, p. 237.
- [4] Brewer GJ. (2001) Zinc acetate for the treatment of Wilson's disease. *Expert Opin Pharmacother* 2: 1473-1477.
- [5] Prasad AS. (1979) Clinical, biochemical, and pharmacological role of zinc. *Ann Rev Pharmacol Toxicol* 19: 393-426.
- [6] Supuran CT. (2008) Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Dis* 7: 168-181.
- [7] Elmes ME. (1975) Letter: Zinc in human medicine. *Lancet* 2: 549.
- [8] Mazumder PM, Pattnayak S, Parvani H, Sasmal D, Rathinavelusamy P. (2012) Evaluation of immunomodulatory activity of *Glycyrrhiza glabra* L. roots in combination with zing. *Asian Pac J Trop Biomed* 2: S15-S20.
- [9] Brynestad J, Yakel HL. (1978) Preparation and structure of anhydrous zinc chloride. *Inorg Chem* 17: 1376-1377.
- [10] Kasture AV, Wadodkar SG. (2008) A text book of pharmaceutical chemistry-1, Nirali Prakashan, 25th Ed., Pune, India.
- [11] Mahadik KR, Kuchekar BS. (2008) Concise inorganic pharmaceutical chemistry, Nirali Prakashan, 25th Ed., Pune, India.
- [12] McDaniel S, Goldman GD. (2002) Consequences of using escharotic agents as primary treatment for nonmelanoma skin cancer. *Arch Dermatol* 138: 1593-1596.
- [13] Hu J, Yang Z, Wang J, Yu J, Guo J, Liu S, Qian C, Song L, Wu Y, Cheng J. (2016) Zinc chloride transiently maintains mouse embryonic stem cell pluripotency by activating Stat3 signaling. *PLoS One* 11: e0148994.
- [14] Fukuyama Y, Kawarai S, Tezuka T, Kawabata A, Maruo T. (2016) The palliative efficacy of modified Mohs paste for controlling canine and feline malignant skin wounds. *Vet Q.* 1: 1-7.
- [15] Yakimovskii AF, Kryzhanovskaya SY. (2015) Zinc chloride and zinc acetate injected into the neostriatum produce opposite effect on locomotor behavior of rats. *Bull Exp Biol Med* 160: 281-282.
- [16] Stenger VJ. (1999) Bioenergetic fields. *Sci Rev Alternative Med* 3: 16-21.
- [17] Rogers, M. (1989) "Nursing: A. Science of Unitary Human Beings." In J. P. Riehl-Sisca (ed.) *Conceptual Models for Nursing Practice*. 3rd Edn. Norwalk: Appleton & Lange.
- [18] Rosa L, Rosa E, Sarner L, Barrett S. (1998) A close look at therapeutic touch. *Journal of the American Medical Association* 279: 1005-1010.
- [19] Warber SL, Cornelio D, Straughn, J, Kile G. (2004) Biofield energy healing from the inside. *J. Altern Complement Med* 10: 1107-1113.
- [20] Koithan M. (2009) Introducing complementary and alternative therapies. *J. Nurse Pract* 5: 18-20.
- [21] Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S. (2015) The potential impact of biofield treatment on human brain tumor cells: A. time-lapse video microscopy. *J Integr Oncol* 4: 141.
- [22] Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S. (2015) An evaluation of biofield treatment on susceptibility pattern of multidrug resistant *Stenotrophomonas maltophilia*: An emerging global opportunistic pathogen. *Clin Microbiol* 4: 211.
- [23] Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S. (2015) An effect of biofield treatment on multidrug-resistant *Burkholderia cepacia*: A. multihost pathogen. *J. Trop Dis* 3: 167.
- [24] Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S. (2015) Phenotypic and biotypic characterization of *Klebsiella oxytoca*: An impact of biofield treatment. *J. Microb Biochem Technol* 7: 203-206.
- [25] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S. (2015) Antibiofilm, biochemical reactions and genotyping characterization of biofield treated *Staphylococcus aureus*. *American Journal of BioScience* 3: 212-220.
- [26] Trivedi MK, Branton A, Trivedi D, Nayak G, Bairwa K, Jana S. (2015) Physical, thermal, and spectroscopic characterization of biofield energy treated potato micropropagation medium. *American Journal of Bioscience and Bioengineering* 3: 106-113.
- [27] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S. (2015) Biochemical differentiation and molecular characterization of biofield treated *Vibrio parahaemolyticus*. *American Journal of Clinical and Experimental Medicine* 3: 260-267.
- [28] Trivedi MK, Branton A, Trivedi D, Gangwar M, Jana S. (2015) Antimicrobial susceptibility, biochemical characterization and molecular typing of biofield treated *Klebsiella pneumoniae*. *J Health Med Inform* 6: 206.
- [29] Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, Latiyal O, Jana S (2015) Analysis of physical, thermal, and structural properties of biofield energy treated molybdenum dioxide. *International Journal of Materials Science and Applications* 4: 354-359.
- [30] Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, Latiyal O, Jana S. (2015) Characterization of atomic and physical properties of biofield energy treated manganese sulfide powder. *American Journal of Physics and Applications* 3: 215-220.
- [31] Trivedi MK, Branton A, Trivedi D, Nayak G, Saikia G, Jana S. (2015) Physical and structural characterization of biofield treated imidazole derivatives. *Nat Prod Chem Res* 3: 187.
- [32] Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, Mishra RK, Jana S. (2015) Characterization of physical, spectral and thermal properties of biofield treated 1,2,4-Triazole. *J. Mol Pharm Org Process Res* 3: 128.
- [33] Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, Mishra RK, Jana S. (2015) Biofield treatment: A. potential strategy for modification of physical and thermal properties of gluten hydrolysate and ipomoea macroelements. *J. Nutr Food Sci* 5: 414.

- [34] Trivedi MK, Nayak G, Patil S, Tallapragada RM, Jana S, Mishra RK. (2015) Bio-field Treatment: An effective strategy to improve the quality of beef extract and meat infusion powder. *J. Nutr Food Sci* 5: 389.
- [35] Trivedi MK, Branton A, Trivedi D, Nayak G, Latiyal O, Jana S. (2015) Evaluation of biofield treatment on atomic and thermal properties of ethanol. *Organic Chem Curr Res* 4: 145.
- [36] Trivedi MK, Branton A, Trivedi D, Nayak G, Singh R, Jana S. (2015) Physical, thermal and spectroscopic studies on biofield treated *p*-dichlorobenzene. *Biochem Anal Biochem* 4: 204.
- [37] Trivedi MK, Branton A, Trivedi D, Nayak G, Bairwa K, Jana S. (2015) Physicochemical and spectroscopic characterization of biofield energy treated *p*-anisidine. *Pharm Anal Chem Open Access* 6: 102.
- [38] Trivedi MK, Branton A, Trivedi D, Nayak G, Gangwar M, Jana S. (2015) Agronomic characteristics, growth analysis, and yield response of biofield treated mustard, cowpea, horse gram, and groundnuts. *International Journal of Genetics and Genomics* 3: 74-80.
- [39] Trivedi MK, Branton A, Trivedi D, Nayak G, Gangwar M, Jana S. (2015) Analysis of genetic diversity using simple sequence repeat (SSR) markers and growth regulator response in biofield treated cotton (*Gossypium hirsutum* L.). *American Journal of Agriculture and Forestry* 3: 216-221.
- [40] Cherson R. (2009) Bioavailability, bioequivalence, and drug selection. In: Makoid CM, Vuchetich PJ, Banakar UV (Eds) *Basic pharmacokinetics* (1st Edn) Pharmaceutical Press, London.
- [41] Blagden N, de Matas M, Gavan PT, York P. (2007) Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. *Adv Drug Deliv Rev* 59: 617-630.
- [42] Trivedi MK, Mohan TRR (2016) Biofield energy signals, energy transmission and neutrinos. *American Journal of Modern Physics* 5: 172-176.
- [43] Alexander L, Klug HP. (1950) Determination of crystallite size with the X-Ray Spectrometer. *J. App Phys* 21: 137.
- [44] Langford JJ, Wilson AJC. (1978) Scherrer after sixty years: A survey and some new results in the determination of crystallite size. *J. Appl Cryst* 11: 102-113.
- [45] Inoue M, Hirasawa I. (2013) The relationship between crystal morphology and XRD peak intensity on CaSO₄.2H₂O. *J. Crystal Growth* 380: 169-175.
- [46] Raza K, Kumar P, Ratan S, Malik R, Arora S. (2014) Polymorphism: The phenomenon affecting the performance of drugs. *SOJ Pharm Pharm Sci* 1: 10.
- [47] Thiruvengadam E, Vellaisamy G. (2014) Polymorphism in pharmaceutical ingredients a review. *World Journal of Pharmacy and Pharmaceutical Sciences* 3: 621-633.
- [48] <http://www.dissolution.com/ddg/showthread.php?2366-Surface-Area-vs-Particle-Size>.
- [49] Mosharrof M, Nyström C. (1995) The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. *Int J Pharm* 122: 35-47.
- [50] Murray HH, Lyons SC (1960) Further correlation of kaolinite crystallinity with chemical and physical properties. *Clays Clay Miner* 8: 11-17.
- [51] Sun J, Wang F, Sui Y, She Z, Zhai W, Wang C, Deng Y. (2012) Effect of particle size on solubility, dissolution rate, and oral bioavailability: Evaluation using coenzyme Q₁₀ as naked nanocrystals. *Int J. Nanomed* 7: 5733-5744.
- [52] Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, Cho JM, Yun G, Lee J. (2014) Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. *Asian J Pharm Sci* 9: 304-316.
- [53] Buckton G, Beezer AE. (1992) The relationship between particle size and solubility. *Int J Pharmaceutics* 82: R7-R10.
- [54] Stuart BH. (2004) *Infrared spectroscopy: Fundamentals and applications in Analytical Techniques in the Sciences*. John Wiley & Sons Ltd., Chichester, UK.
- [55] Hesse M, Meier H, Zeeh B. (1997) *Spectroscopic methods in organic chemistry*, Georg Thieme Verlag Stuttgart, New York.
- [56] Bajaj S, Singla D, Sakhuja N. (2012) Stability testing of pharmaceutical products. *J App Pharm Sci* 2: 129-138.